The FDA cleared Altius as an aid in the management of chronic intractable phantom and residual lower limb post-amputation pain in adult amputees. Labeling came on the back of results from the QUEST study, which met all primary efficacy and safety endpoints.

Aliso Viejo, California-based Neuros said Altius demonstrated superiority of treatment over active-sham control in the QUEST study. Patients receiving Altius reported statistically significant and lasting reductions in pain. They also reported decreased opioid use and improvements in quality of life.